
MALI Platform
AI Stock Research
RA Capital Management, L.P.: latest 13F holdings
For the quarter ending 30 September 2026, RA Capital Management, L.P. reported 92 positions worth $10.0B in total, filed with the SEC on 16 November 2026. The quarter before, it reported $11.5B.
Read the filing at SEC EDGARChecked: the cover page's entry count and total value match the holdings table.
Top 50 positions by value
| # | Issuer | Class | Value | Weight | Shares | vs quarter before |
|---|---|---|---|---|---|---|
| 1 | ASCENDIS PHARMA A/S | Common Stock | $2.3B | 23.50% | 10,281,496 | Unchanged |
| 2 | PARABILIS MEDICINES INC | Common Stock | $942.2M | 9.45% | 29,177,964 | Added 0.8% |
| 3 | VAXCYTE INC | Common Stock | $652.9M | 6.55% | 11,474,599 | Unchanged |
| 4 | RHYTHM PHARMACEUTICALS INC | Common Stock | $634.8M | 6.37% | 6,666,837 | Unchanged |
| 5 | EDGEWISE THERAPEUTICS INC | Common Stock | $340.7M | 3.42% | 8,392,730 | Unchanged |
| 6 | TYRA BIOSCIENCES INC | Common Stock | $266.8M | 2.68% | 12,198,625 | Unchanged |
| 7 | FREENOME INC | Common Stock | $242.0M | 2.43% | 15,367,270 | New |
| 8 | HEMAB THERAPEUTICS HOLDINGS | Common Stock | $240.8M | 2.42% | 7,808,627 | Unchanged |
| 9 | NEWAMSTERDAM PHARMA CO NV | Common Stock | $232.3M | 2.33% | 9,550,191 | Unchanged |
| 10 | SEPTERNA INC | Common Stock | $215.3M | 2.16% | 5,502,858 | Cut 21.3% |
| 11 | SPYGLASS PHARMA INC | Common Stock | $208.5M | 2.09% | 8,021,117 | Unchanged |
| 12 | JANUX THERAPEUTICS INC | Common Stock | $193.4M | 1.94% | 11,189,693 | Unchanged |
| 13 | MINERALYS THERAPEUTICS INC | Common Stock | $193.3M | 1.94% | 7,692,750 | Unchanged |
| 14 | DISC MEDICINE INC | Common Stock | $160.4M | 1.61% | 2,450,221 | Unchanged |
| 15 | TAYSHA GENE THERAPIES INC | Common Stock | $148.2M | 1.49% | 30,435,190 | Added 29.2% |
| 16 | BICARA THERAPEUTICS INC | Common Stock | $135.0M | 1.35% | 7,255,993 | Unchanged |
| 17 | ARTIVA BIOTHERAPEUTICS INC | Common Stock | $131.6M | 1.32% | 18,489,293 | Added 3.0% |
| 18 | XENCOR INC | Common Stock | $131.6M | 1.32% | 5,274,274 | Unchanged |
| 19 | ORUKA THERAPEUTICS INC | Common Stock | $129.5M | 1.30% | 1,554,597 | Unchanged |
| 20 | AMYLYX PHARMACEUTICALS INC | Common Stock | $124.5M | 1.25% | 4,279,341 | New |
| 21 | CLIMB BIO INC | Common Stock | $116.2M | 1.17% | 10,130,130 | Cut 10.4% |
| 22 | ABIVAX SA-ADR | ADR | $102.0M | 1.02% | 1,030,058 | Cut 9.1% |
| 23 | WAVE LIFE SCIENCES INC | Common Stock | $99.8M | 1.00% | 26,975,505 | New |
| 24 | LATIGO BIOTHERAPEUTICS INC | Common Stock | $88.6M | 0.89% | 5,302,933 | New |
| 25 | SOLID BIOSCIENCES INC | Common Stock | $87.0M | 0.87% | 12,036,126 | Unchanged |
| 26 | VOR BIOPHARMA INC | Common Stock | $85.9M | 0.86% | 4,503,882 | Added 87.5% |
| 27 | LB PHARMACEUTICALS INC | Common Stock | $84.8M | 0.85% | 2,208,604 | Unchanged |
| 28 | GH RESEARCH PLC | Common Stock | $84.7M | 0.85% | 3,609,007 | Cut 52.7% |
| 29 | OBSIDIAN THERAPEUTICS INC | Common Stock | $81.8M | 0.82% | 5,957,103 | New |
| 30 | ZAI LAB LTD-ADR | ADR | $74.2M | 0.74% | 2,815,543 | Cut 51.0% |
| 31 | 4D MOLECULAR THERAPEUTICS IN | Common Stock | $72.3M | 0.72% | 5,049,779 | Unchanged |
| 32 | ACLARIS THERAPEUTICS INC | Common Stock | $66.9M | 0.67% | 12,723,026 | Unchanged |
| 33 | SANA BIOTECHNOLOGY INC | Common Stock | $54.7M | 0.55% | 18,750,000 | Unchanged |
| 34 | MONOPAR THERAPEUTICS INC | Common Stock | $53.2M | 0.53% | 667,207 | Unchanged |
| 35 | GERON CORP | Common Stock | $52.6M | 0.53% | 42,754,145 | Cut 0.1% |
| 36 | DAMORA THERAPEUTICS INC | Common Stock | $51.1M | 0.51% | 2,399,702 | New |
| 37 | PEPGEN INC | Common Stock | $48.6M | 0.49% | 20,064,545 | Unchanged |
| 38 | ARS PHARMACEUTICALS INC | Common Stock | $46.8M | 0.47% | 10,860,977 | Unchanged |
| 39 | ACUMEN PHARMACEUTICALS INC | Common Stock | $46.6M | 0.47% | 20,992,669 | Unchanged |
| 40 | DBV TECHNOLOGIES SA-SPON ADR | Common Stock | $43.0M | 0.43% | 3,657,644 | New |
| 41 | AGENUS INC | Common Stock | $40.9M | 0.41% | 4,122,000 | New |
| 42 | REZOLUTE INC | Common Stock | $39.1M | 0.39% | 9,445,039 | Unchanged |
| 43 | SIONNA THERAPEUTICS INC | Common Stock | $34.0M | 0.34% | 6,456,234 | Cut 34.8% |
| 44 | SCRIBE THERAPEUTICS INC | Common Stock | $33.2M | 0.33% | 1,802,178 | New |
| 45 | CENTURY THERAPEUTICS INC | Common Stock | $30.4M | 0.30% | 17,754,430 | Unchanged |
| 46 | EVOMMUNE INC | Common Stock | $28.9M | 0.29% | 3,494,638 | Unchanged |
| 47 | KORSANA BIOSCIENCES INC | Common Stock | $28.6M | 0.29% | 892,743 | New |
| 48 | CAPRICOR THERAPEUTICS INC | Common Stock | $28.5M | 0.29% | 3,014,183 | Added 99.9% |
| 49 | NKARTA INC | Common Stock | $28.3M | 0.28% | 10,805,129 | Unchanged |
| 50 | C4 THERAPEUTICS INC | Common Stock | $27.3M | 0.27% | 8,194,779 | Added 2.4% |
Showing the largest 50 of 92 positions. Every position is in MALI's SEC Financials & 13F workspace.
New this quarter
- FREENOME INC · $242.0M
- AMYLYX PHARMACEUTICALS INC · $124.5M
- WAVE LIFE SCIENCES INC · $99.8M
- LATIGO BIOTHERAPEUTICS INC · $88.6M
- OBSIDIAN THERAPEUTICS INC · $81.8M
- DAMORA THERAPEUTICS INC · $51.1M
- DBV TECHNOLOGIES SA-SPON ADR · $43.0M
- AGENUS INC · $40.9M
- SCRIBE THERAPEUTICS INC · $33.2M
- KORSANA BIOSCIENCES INC · $28.6M
Sold out
- BIOCRYST PHARMACEUTICALS INC · was $158.3M
- WAVE LIFE SCIENCES LTD · was $156.7M
- NUVALENT INC-A · was $153.9M
- INTELLIA THERAPEUTICS INC · was $76.6M
- DEFINIUM THERAPEUTICS INC · was $70.6M
- DAMORA THERAPEUTICS INC · was $62.4M
- AKTIS ONCOLOGY INC · was $42.4M
- BIOAGE LABS INC · was $41.0M
- KARYOPHARM THERAPEUTICS INC · was $18.7M
- WAYSTAR HOLDING CORP · was $10.9M
Reading a 13F
A 13F lists a manager's long positions in US-listed securities at the end of a quarter, filed up to 45 days later. It leaves out short positions, cash and most non-US holdings, so it is a partial, delayed view of a portfolio. Nothing here is investment advice.
Positions are named as the manager filed them. Values are the filing's own, in US dollars; changes compare share counts with the quarter before.